Nuklearmedizin 2023; 62(02): 86
DOI: 10.1055/s-0043-1766149
Abstracts | NuklearMedizin 2023
Leuchtturm
Onkologie - Radioligandentherapie

First-in-human Study of an Optimized, Kit-type, SSTR Antagonist 68Ga-DATA5m-LM4 in Patients with Metastatic Neuroendocrine Tumors

J. Zhang
1   National University of Singapore, Singapore
,
L. Greifenstein
2   CURANOSTICUM Wiesbaden–Frankfurt, Zentrum für Molekulare Radiotherapie in der Deutschen Klinik für Diagnostik (DKD Helios Klinik), Wiesbaden
,
V. Jakobsson
1   National University of Singapore, Singapore
,
C. S. Kramer
2   CURANOSTICUM Wiesbaden–Frankfurt, Zentrum für Molekulare Radiotherapie in der Deutschen Klinik für Diagnostik (DKD Helios Klinik), Wiesbaden
,
E. Zan
3   Department of Radiology, New York University Langone Medical Center, New York, NY, USA
,
A. Klega
2   CURANOSTICUM Wiesbaden–Frankfurt, Zentrum für Molekulare Radiotherapie in der Deutschen Klinik für Diagnostik (DKD Helios Klinik), Wiesbaden
,
F. Rösch
4   Johannes Gutenberg-Universität, Department of Chemistry – TRIGA site, Mainz
,
C. Landvogt
2   CURANOSTICUM Wiesbaden–Frankfurt, Zentrum für Molekulare Radiotherapie in der Deutschen Klinik für Diagnostik (DKD Helios Klinik), Wiesbaden
,
C. Müller
2   CURANOSTICUM Wiesbaden–Frankfurt, Zentrum für Molekulare Radiotherapie in der Deutschen Klinik für Diagnostik (DKD Helios Klinik), Wiesbaden
,
R. P. Baum
2   CURANOSTICUM Wiesbaden–Frankfurt, Zentrum für Molekulare Radiotherapie in der Deutschen Klinik für Diagnostik (DKD Helios Klinik), Wiesbaden
› Author Affiliations
› Further Information
 

Ziel/Aim To assess the feasibility of using a novel kit-type SSTR antagonist 68Ga-DATA5m-LM4 for PET imaging and evaluate the safety, biodistribution and preliminary diagnostic efficacy of it in patients with metastatic neuroendocrine tumors.

Methodik/Methods A total of 27 patients (19 male, 8 female; mean age, 61.0±12.1y) with histopathologically confirmed well-differentiated NETs underwent 68Ga-DATA5m-LM4 PET/CT for staging, restaging or patient selection. All the patients underwent PET/CT scans 60min after i.v. 1.85 MBq (0.05 mCi) per kg body weight (151±54 MBq) of 68Ga-DATA5m-LM4. Biodistribution in normal organs, lesion detection ability, tumor uptake as well as comparison with agonist TATE/TOC was analyzed.

Ergebnisse/Results 68Ga-DATA5m-LM4 was labeled with 68Ga with high yield and purity. 68Ga -DATA5m-LM4 was well tolerated in all patients. Normal organ uptake of 68Ga-DATA5m-LM4 in thyroid gland, pancreas, and spleen was significantly lower (P<0.05), compared to 68Ga-DOTA-TATE (3.90±0.88 vs 9.12±3.64, P<0.000001), particularly in the liver, and in liver and spleen significantly lower than 68Ga-DOTA-TOC uptake (P=0.0166 and P=0.0098, respectively). NET lesions showed high uptake (SUVmax up to 167.93, mean±SD, 44.47±36.22. With SUVmean of healthy liver, kidney, and blood pool as background, tumor-to-background ratios were 20.32±19.97, 4.30±3.03, and 38.63±35.97.

Schlussfolgerungen/Conclusions The new SSTR antagonist 68Ga-DATA5m-LM4 can be conveniently labeled with high radiochemical yields and purities. Our first clinical data demonstrate excellent imaging performance of the new SSTR antagonist 68Ga-DATA5m-LM4. Application of this tracer in patients with disseminated NET metastases showed superior biodistribution with very high tumor contrast and low uptake in thyroid and spleen, and especially in the liver as compared to SSTR agonists, which facilitates lesion detection. The advantageous imaging characteristics, along with the convenient, „kit-type” production, makes 68Ga-DATA5m-LM4 an overall extraordinary promising radiopharmaceutical for staging and restaging of NET patients and especially for the detection of very small hepatic metastases.



Publication History

Article published online:
30 March 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany